Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Lisa, Neumeier"'
Autor:
Lisa Neumeier, Kelly McIntosh, Adam S. Nelson, Adam Lane, Min Dong, Tsuyoshi Fukuda, Danielle E. Arnold, Parinda A. Mehta, Federica Achini, Sharat Chandra, Arjan C. Lankester, Alexander A. Vinks, Ashley Teusink-Cross, Chie Emoto, Rebecca A. Marsh, Michael B. Jordan, Kasiani C. Myers, Stella M. Davies
Publikováno v:
Bone Marrow Transplantation. SPRINGERNATURE
Bone Marrow Transplantation
Bone Marrow Transplantation
Alemtuzumab is used as part of reduced-intensity and reduced-toxicity transplant conditioning regimens for nonmalignant diseases. Prior studies identified an ideal target concentration range of 0.15-0.6 mcg/mL at day 0. However, only 24% of patients
Autor:
Danielle E, Arnold, Chie, Emoto, Tsuyoshi, Fukuda, Min, Dong, Alexander A, Vinks, Adam, Lane, Kelly, McIntosh, Lisa, Neumeier, Arjan C, Lankester, Federica, Achini, Ashley, Teusink-Cross, Sharat, Chandra, Michael B, Jordan, Adam S, Nelson, Kasiani C, Myers, Stella M, Davies, Parinda A, Mehta, Rebecca A, Marsh
Publikováno v:
Bone marrow transplantation. 56(12)
Alemtuzumab is used as part of reduced-intensity and reduced-toxicity transplant conditioning regimens for nonmalignant diseases. Prior studies identified an ideal target concentration range of 0.15-0.6 mcg/mL at day 0. However, only 24% of patients
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e43859 (2012)
The migration of T lymphocytes is an essential part of the adaptive immune response as T cells circulate around the body to carry out immune surveillance. During the migration process T cells polarize, forming a leading edge at the cell front and a u
Externí odkaz:
https://doaj.org/article/6115844ae3d44e51b18f24cf2cc78111
Autor:
Parinda A. Mehta, Chie Emoto, Ashley Teusink-Cross, Lisa Neumeier, Sharat Chandra, Rebecca A. Marsh, Alexander A. Vinks, Tsuyoshi Fukuda, Pooja Khandelwal
Publikováno v:
Biology of Blood and Marrow Transplantation. 23:635-641
Alemtuzumab is frequently used as part of reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (HCT) in pediatric patients with nonmalignant diseases. We previously suggested an optimal day 0 targeted range
Autor:
Adam Lane, Stella M. Davies, Lisa Neumeier, Rebecca A. Marsh, Parinda A. Mehta, Alexandra H. Filipovich, Sonata Jodele
Publikováno v:
Blood. 127:503-512
Reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) with alemtuzumab, fludarabine, and melphalan is an effective approach for patients with nonmalignant disorders. Mixed chimerism and graft-versus-host-disease (GV
Autor:
Lisa Neumeier, Stella M. Davies, Adam Lane, Kasiani C. Myers, Adam S. Nelson, Michael B. Jordan, Rebecca A. Marsh, Ashley Teusink-Cross, Alexander A. Vinks, Tsuyoshi Fukuda, Parinda A. Mehta, Danielle E. Arnold, Sharat Chandra, Chie Emoto
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S150
Background Alemtuzumab is frequently used as part of reduced-intensity and reduced-toxicity conditioning regimens. High alemtuzumab levels at day 0 are associated with decreased rates of acute graft-versus-host disease (aGVHD) but increased rates of
Autor:
Adam Lane, Lisa Neumeier, Alan Howard, Carl E. Allen, Parinda A. Mehta, Michael A. Pulsipher, Stella M. Davies, Rebecca A. Marsh, M. Christa Krupski
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S228-S229
A reduced intensity conditioning regimen consisting of alemtuzumab, fludarabine, and melphalan has been shown to be associated with superior survival in patients with hemophagocytic lymphohistiocytosis, but is complicated by a high risk of mixed chim
Autor:
Lisa Neumeier, Stella M. Davies, Tsuyoshi Fukuda, Javier El-Bietar, Michael B. Jordan, Kasiani C. Myers, Rebecca A. Marsh, Chie Emoto, Sonata Jodele, Christopher E. Dandoy, Alexander A. Vinks, J.J. Bleesing, Sharat Chandra, Michael Grimley, Ashish R Kumar, Pooja Khandelwal, Parinda A. Mehta
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 22(12)
We describe a single-center prospective study of alemtuzumab as a second-line agent for steroid-refractory (SR) acute graft-versus-host disease (aGVHD) in pediatric and young adult allogeneic hematopoietic stem cell transplant recipients. Alemtuzumab
Autor:
Lisa Neumeier, Parinda A. Mehta, Stella M. Davies, Alexandra H. Filipovich, Rebecca A. Marsh, Sonata Jodele
Publikováno v:
Biology of Blood and Marrow Transplantation. 22(3)
Autor:
Scott M. Gordon, Lisa Neumeier, Zerrin Kuras, Ameet A. Chimote, Alexandra H. Filipovich, Volodymyr Kucher, Laura Conforti
Publikováno v:
American Journal of Physiology-Cell Physiology. 302:C1504-C1512
The cAMP/PKA signaling system constitutes an inhibitory pathway in T cells and, although its biochemistry has been thoroughly investigated, its possible effects on ion channels are still not fully understood. KV1.3 channels play an important role in